Eli Lilly completes acquisition of Dice Therapeutics

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of DICE Therapeutics (DICE). The acquisition expands Lilly’s immunology portfolio to include DICE’s novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. DICE’s common stock will be delisted from the NASDAQ Global Market.